lorcaserin (EPX-200) / Paragon Biosciences - LARVOL DELTA

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome (PRNewswire) - "Epygenix Therapeutics, Inc...announced today that the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation to EPX-200 for the treatment of patients with Dravet syndrome (DS) based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA)."

Orphan drug • CNS Disorders • Epilepsy

Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. (PubMed, Expert Opin Drug Discov) - "Experimental data and results from initial clinical studies have brought attention to several drugs with various mechanisms of action including: ataluren (a suppressant of premature stop codons; under clinical evaluation), EPX-100, EPX-200, fenfluramine (serotonin modulators), soticlestat (an 24-hydroxylase cholesterol enzyme inhibitor), SPN-817 (an inhibitor of acetylcholinesterase), verapamil (a voltage-dependent calcium channel inhibitor) and STK-001 (an antisense oligonucleotide). The latter is scheduled for clinical evaluation."

Journal • CNS Disorders • Epilepsy